


RealRate

PHARMACEUTICAL 2023



Lantern Pharma Inc. Rank 31 of 446





PHARMACEUTICAL 2023





Lantern Pharma Inc. Rank 31 of 446

The relative strengths and weaknesses of Lantern Pharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lantern Pharma Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 92% points. The greatest weakness of Lantern Pharma Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 266%, being 223% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	58,723
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,798
Liabilities, Non-Current	0
Other Assets	66
Other Compr. Net Income	-279
Other Expenses	0
Other Liabilities	0
Other Net Income	173
Other Revenues	0
Property and Equipment	48
Research and Development	8,603
Selling, General and Administrative Expense	5,830

Output Variable	Value in 1000 USD
Assets	58,836
Liabilities	2,798
Expenses	14,433
Revenues	0
Stockholders Equity	56,038
Net Income	-14,260
Comprehensive Net Income	-14,399
Economic Capital Ratio	266%

